Agenus (AGEN) +7.3% premarket after announcing efficacy shown with GlaxoSmithKline's (GSK) Phase...


Agenus (AGEN) +7.3% premarket after announcing efficacy shown with GlaxoSmithKline's (GSK) Phase 3 malaria vaccine candidate, which contains AGEN's Qs-21 Stimulon adjuvant. Infants at the trial receiving the vaccine experienced one-third fewer episodes of both clinical and severe malaria.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs